You are here

thyroid cancer

Lilly’s Retevmo Shows Superior Survival in Phase III Thyroid Cancer Trial

Lilly’s Retevmo Shows Superior Survival in Phase III Thyroid Cancer Trial

BioSpace

medullary thyroid cancer

clinical trials

Flag link:

Novo Nordisk says EMA raised safety signal on drugs including semaglutide

Novo Nordisk says EMA raised safety signal on drugs including semaglutide

Yahoo/Reuters

Flag link:

Exelixis pulls a surprise win in thyroid cancer just days ahead of final Cabometyx readout

Exelixis pulls a surprise win in thyroid cancer just days ahead of final Cabometyx readout

Endpoints

Flag link:

ASCO: Exelixis releases more details on Cabometyx thyroid cancer data that wooed Ipsen

ASCO: Exelixis releases more details on Cabometyx thyroid cancer data that wooed Ipsen

Fierce Pharma

clinical trials

Flag link:

Exelixis' Cabometyx scores backing from Ipsen in thyroid cancer, with full data release set for ASCO

Exelixis' Cabometyx scores backing from Ipsen in thyroid cancer, with full data release set for ASCO

Fierce Pharma

Flag link:

Roche, Blueprint raise pressure on Lilly with new Gavreto approval

Roche, Blueprint raise pressure on Lilly with new Gavreto approval

Pharmaforum

Blueprint Medicines

Flag link:

Racing Blueprint, Lilly drug gets priority review for RET hopeful

Racing Blueprint, Lilly drug gets priority review for RET hopeful

Fierce Biotech

Blueprint Medicines

non-small cell lung cancer

Flag link:

AI Mines Clinical Data for Thyroid Cancer Therapeutic Targets

AI Mines Clinical Data for Thyroid Cancer Therapeutic Targets

Medical Devices and Diagnostics Industry

artificial intelligence

Predictive Oncology

Interpace Diagnostics

Flag link:

Exelixis Hits Blockbuster Status

Exelixis Hits Blockbuster Status

Motley Fool

Flag link:

Veracyte Presents Data Demonstrating Afirma's Success in Reducing Unnecessary Surgery

Veracyte Presents Data Demonstrating Afirma's Success in Reducing Unnecessary Surgery

CP Wire

thyroid nodules

Flag link:

Veracyte Presents Data Demonstrating Afirma's Success in Reducing Unnecessary Surgery

Flag link:

Exelixis Begins Ph III Trial of Cabometyx in Refractory Thyroid Cancer

Exelixis Begins Ph III Trial of Cabometyx in Refractory Thyroid Cancer

CP Wire

Flag link:

Exelixis Begins Ph III Trial of Cabometyx in Refractory Thyroid Cancer

Flag link:

Could a New Imaging Device Curb Thyroid Cancer?

Could a New Imaging Device Curb Thyroid Cancer?

Medical Devices and Diagnostics Industry

Flag link:

Eisai's Lenvima posts big growth numbers as Merck collaboration rolls into action

Eisai's Lenvima posts big growth numbers as Merck collaboration rolls into action

Fierce Pharma

Flag link:

AstraZeneca’s selumetinib flops in thyroid cancer, adding to list of failures

AstraZeneca’s selumetinib flops in thyroid cancer, adding to list of failures

Fierce Biotech

Flag link:

Eisai's launch for 'crown jewel' Lenvima tracking better than execs expected

Eisai's launch for 'crown jewel' Lenvima tracking better than execs expected

Fierce Pharma Marketing

Flag link:

Eisai Says New Cancer Drug Reaching Patients Faster Than Planned

Eisai Says New Cancer Drug Reaching Patients Faster Than Planned

Bloomberg

Flag link:

Eisai gets EMA nod for Lenvima just weeks after FDA approval

Eisai gets EMA nod for Lenvima just weeks after FDA approval

Fierce Pharma

Flag link:

Can Eisai pump its thyroid cancer pill to $1B in sales? Rival Bayer might object

Can Eisai pump its thyroid cancer pill to $1B in sales? Rival Bayer might object

Fierce Pharma Marketing

Flag link:

Pages